Jordan W. Henry, MHA, MAOL, CAIE, FAHM Veritas AI Consulting Firm.
In my two decades spanning AI ethics and governance, biosecurity policy, public health preparedness and response, and emergency management—including specialized training in responding to domestic biological incidents—I have witnessed how emerging technologies can safeguard or imperil humanity.
The convergence of advanced AI and biotechnology exemplifies this. As someone who has led cross-sector initiatives to integrate ethical frameworks into high-stakes operations, I see AI as a powerful amplifier of both innovation and risk in the life sciences. Frontier AI models now outperform expert virologists on complex benchmarks, lowering barriers for malicious actors to design or enhance pathogens.
Businesses in biotech, pharmaceuticals, healthcare and AI development cannot treat this as a distant regulatory issue. The 2025 policy landscape—including dual-use research oversight updates and new National Defense Authorization Act provisions on AI-ready biological data—signals that voluntary leadership today will shape mandatory standards tomorrow. Drawing from my experience coordinating emergency responses and crafting AI governance strategies, this article outlines core biosecurity risks at the AI-ethics intersection and delivers actionable guardrails as business tools for mitigation.
The AI-Biosecurity Convergence: Why Risks Are Accelerating
AI systems, especially dual-use foundation models and specialized biological AI models (BAIMs), are transforming synthetic biology. They accelerate protein design and protocol troubleshooting but also democratize dangerous knowledge. Recent evaluations show leading models generating plausible ideas for pathogen modification, evading DNA synthesis screening or providing step-by-step guidance that could assist nonexperts in bioweapon pathways.
These risks are not hypothetical. In 2025, multiple AI developers imposed additional safeguards after internal testing revealed models could meaningfully aid novices in biological weapons development. Agentic AI systems—those capable of autonomous planning and iteration—exacerbate the problem by chaining biological design tools with general-purpose reasoning, potentially compressing timelines from ideation to execution.
From an ethical standpoint, this raises profound questions of equity, accountability and human well-being. In public health emergencies I have managed, the speed of information determined outcomes. AI amplifies this dynamic. Biased or unverified outputs can erode trust in pandemic response, while unchecked dual-use capabilities disproportionately threaten vulnerable populations globally.
My background in emergency management underscores a parallel: We already possess frameworks like the Incident Command System (ICS) for all-hazards preparedness. Applying similar structured coordination to AI-biosecurity risks is a governance imperative.
Ethical Foundations: Lessons From AI Governance And Public Health Preparedness
AI ethics must be embedded in biosecurity strategy. Core principles—transparency, accountability, inclusivity and sustainability—align directly with public health doctrines I have applied in real-world responses. The NIST AI Risk Management Framework (RMF) and its Generative AI Profile provide a voluntary but robust structure for mapping, measuring and managing risks, now explicitly extended to chemical and biological misuse in updated guidance.
International efforts, such as those from NTI | bio and the Frontier Model Forum, emphasize layered defenses: technical guardrails in models, managed access controls for high-risk tools and downstream synthesis screening—mirroring the multilayered preparedness (prevention, detection, response, recovery) advocated in emergency management.
Businesses that ignore this intersection risk not only catastrophic harm but also regulatory scrutiny, reputational damage and loss of stakeholder trust. Proven, scalable tools exist.
Essential Guardrails: A Business Toolkit For Mitigation
Here are practical, implementation-ready guardrails informed by my experience bridging AI ethics with biosecurity and emergency operations. Adopt them as a layered system, much like ICS command structures.
1. Establish an AI-biosecurity risk governance committee. Mirror emergency management’s unified command model; include AI ethicists, biosecurity experts, legal/compliance leads and C-suite representation. Charge it with annual risk assessments using NIST AI 800-1 guidelines for dual-use foundation models. Document thresholds (e.g., performance on the Virology Capabilities Test or DNA synthesis evasion benchmarks) that trigger enhanced safeguards or deployment pauses. Adapt the NTI-managed access framework for biological design tools—tier access based on validated user credentials and intended use.
2. Implement rigorous red-teaming and adversarial testing. Conduct regular, independent red-team exercises focused on biosecurity misuse scenarios, including prompt injection and jailbreaking. Frontier companies like Anthropic and OpenAI already employ responsible scaling policies with CBRN risk thresholds; businesses downstream should require vendors to disclose results. Integrate automated red-teaming frameworks and partner with organizations like SecureBio or EBRC for domain-specific benchmarks.
3. Deploy technical and procedural safeguards. Embed model-level output filters, refusal mechanisms and audit logging for queries involving high-consequence pathogens, select agents or dual-use research of concern (DURC). Mandate metadata standards for AI-generated sequences (per NTI proposals) and require DNA/RNA synthesis screening compliance. Adopt zero-trust principles and role-based restrictions, especially for internal AI tools handling proprietary biological data. From my emergency management lens, treat these as “containment protocols”—preventing escalation like we do in infectious disease outbreaks.
4. Integrate preparedness and response planning. Develop AI-specific incident response playbooks modeled on public health emergency operations centers. Include monitoring for misuse indicators post-deployment, rapid reporting channels to government partners (leveraging 2025 NDAA and EO provisions) and cross-training staff on ethical decision-making, drawing from WHO AI-for-health ethics principles. Create a “Boundaries of Tolerance” framework defining acceptable risk levels for AI outputs in your sector.
5. Foster transparency, accountability and collaboration. Publish redacted risk assessment summaries (aligned with NIST transparency practices) and participate in industry forums like the Frontier Model Forum. Invest in workforce training that blends AI literacy with biosecurity awareness. Public-private partnerships, as advanced in recent AI and biosecurity policy trends, tend to be force multipliers.
Why Businesses Must Lead—And How To Measure Success
In my Forbes Councils work on ethical AI in healthcare, I emphasized proving real value while protecting public interest. Organizations that embed these guardrails can gain competitive advantages through trust, regulatory foresight and innovation velocity.
Success metrics include reduced high-risk query acceptance rates, audited compliance with frameworks like NIST AI 800-1 and documented participation in cross-sector exercises. Treat this as an all-hazards preparedness exercise—regular drills today prevent disasters tomorrow.
The AI-biosecurity challenge is complex but not insurmountable. By drawing on ethical principles, proven governance and structured response expertise, businesses can turn potential peril into protected progress.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
